Skip to main content
amavitaRESEARCH

FOR PATIENTS - MIAMI

Tomorrow's Heart Treatments -- Available to You at No Cost, in Miami, Today.

Seven active cardiovascular studies. Bilingual coordinators (English and Spanish). World-class investigators. All study-related visits, study medication, and procedures at no cost -- many trials also pay for your time and travel. Apply in 60 seconds and we will call you back the same business day.

Same-day callback / $0 study cost / Bilingual EN-ES

Find My Trial (60-second screening)Call (786) 703-5941

Espanol

New guide: What to Expect When You Join a Cardiovascular Clinical Trial →

Are you a referring physician? See our physician info →

Advanced Cardiovascular of Miami catheterization lab
Affiliated Surgery Center

Advanced cardiovascular care in a comfortable, same-day setting

The only ambulatory surgery center of its kind in South Florida.

All trial-related procedures are performed at our affiliated state-of-the-art surgical center in Miami — the only one of its kind in South Florida — so you receive advanced cardiovascular care in a comfortable, same-day outpatient setting.

9408 SW 87th Ave., Suite 303, Miami, FL 33176

Showing 7 of 7 trials

Phase 1/2Heart FailureActive — enrolling

VASA — Heart Failure with Preserved Ejection Fraction

Heart Failure with Preserved Ejection Fraction (HFpEF)

Protocol: VS-041-102

A safety, tolerability, and biomarker trial of VS-041 in participants with Heart Failure with Preserved Ejection Fraction. Amavita Research Services is an enrolling site under Medpace clinical trial agreement, with Dr. Pedro Martinez-Clark as Principal Investigator.

Sponsor: Vasa Therapeutics, Inc. · PI: Pedro Martinez-Clark, MD, FACC

Key Eligibility

  • Adults with HFpEF (LVEF ≥ 50%)
  • Stable on guideline-directed medical therapy
  • Meeting protocol biomarker criteria
Apply for this trial
Phase 2Heart FailureActive — enrolling

Pfizer C4921003 — PF-07328948 in HFpEF

Heart Failure with Preserved Ejection Fraction (HFpEF)

Protocol: C4921003

Phase 2 study of PF-07328948, an oral branched-chain ketoacid dehydrogenase (BCKD) kinase inhibitor, in adults with heart failure. The trial evaluates the metabolic pathway that branched-chain amino acid catabolism plays in cardiac function in HFpEF.

Sponsor: Pfizer · PI: Pedro Martinez-Clark, MD, FACC

Key Eligibility

  • Adults with HFpEF (LVEF ≥ 50%)
  • On stable guideline-directed medical therapy
  • Meeting protocol metabolic / biomarker criteria
Apply for this trial
Phase 3Heart FailureActive — enrolling

HERMES — Ziltivekimab in Heart Failure

Heart failure with mid-range or preserved ejection fraction and systemic inflammation

Protocol: EX6018-4915

A Phase 3 randomized, placebo-controlled trial evaluating ziltivekimab, a fully human monoclonal antibody targeting interleukin-6, in patients with heart failure and systemic inflammation. Amavita Research Services is an enrolling site, with Dr. Pedro Martinez-Clark as Principal Investigator.

Sponsor: Novo Nordisk · PI: Pedro Martinez-Clark, MD, FACC

Key Eligibility

  • Adults with heart failure (HFmrEF or HFpEF)
  • Evidence of systemic inflammation (e.g., elevated hsCRP)
  • On stable guideline-directed medical therapy
Apply for this trial
Phase 2BHeart FailureActive — start-up

AnaCardio AC01 — Ghrelin Receptor Agonist in HFrEF

Heart Failure with Reduced Ejection Fraction (HFrEF)

Phase 2B study of AC01, an oral ghrelin receptor agonist, administered over 12 weeks in patients with chronic advanced heart failure with reduced ejection fraction (HFrEF). The trial is in site start-up.

Sponsor: AnaCardio AB · PI: Pedro Martinez-Clark, MD, FACC

Key Eligibility

  • Adults with chronic advanced HFrEF
  • On stable guideline-directed medical therapy
  • Meeting protocol functional and biomarker criteria
Apply for this trial
Phase 3Heart FailureActive — enrolling

ICONIC-HF — Ferric Derisomaltose in Iron-Deficiency Heart Failure

Iron-Deficiency Chronic Heart Failure

Protocol: P-Monofer-CHF-02

Phase 3 trial of ferric derisomaltose (intravenous iron) versus no intravenous iron in iron-deficient subjects with symptomatic chronic heart failure. ICONIC-HF measures the impact of IV iron supplementation on HF outcomes.

Sponsor: Pharmacosmos · PI: Pedro Martinez-Clark, MD, FACC

Key Eligibility

  • Adults with symptomatic chronic heart failure
  • Confirmed iron deficiency (TSAT <20% or ferritin criteria)
  • Stable on guideline-directed therapy
Apply for this trial
PivotalVascularActive — enrolling

GREAT — Golazo® Peripheral Atherectomy System

Peripheral Artery Disease

Protocol: AVA-CL-5000

The GREAT Trial evaluates the Golazo® Peripheral Atherectomy System for safe and effective atherectomy in patients with peripheral artery disease. Phase: device IDE study.

Sponsor: Avantec Vascular · PI: Pedro Martinez-Clark, MD, FACC

Key Eligibility

  • Adults 18+ with symptomatic PAD
  • Rutherford Class 2–4
  • Suitable target lesion on imaging
Apply for this trial
Phase 3HypertensionActive — enrolling

ZENITH — Zilebesiran in Uncontrolled Hypertension

Hypertension with Cardiovascular Risk

Protocol: ALN-AGT01-008

Phase 3 study of zilebesiran in patients with hypertension not adequately controlled and with either established cardiovascular disease or high risk for cardiovascular disease. Zilebesiran is a subcutaneous RNAi therapeutic targeting hepatic angiotensinogen.

Sponsor: Alnylam Pharmaceuticals · PI: Dr. William W. O'Neill, MD, FACC

Key Eligibility

  • Adults 18+ with uncontrolled hypertension
  • Established cardiovascular disease or high cardiovascular risk
  • On stable antihypertensive therapy
Apply for this trial

Participation in any clinical trial is voluntary and requires written informed consent reviewed by an Institutional Review Board (IRB) before any study procedure. You may withdraw at any time. Website content is informational and is not a substitute for medical advice from a licensed clinician.

Have questions before joining a trial?

Honest answers about safety, payment, time commitment, your rights, and more.

Read the Patient FAQ

FAQ

Frequently Asked Questions

Common questions from patients exploring clinical trial participation at Amavita Research.